Skip to content
Signal Bureau What’s happening · what the record shows

Pfizer

One of the world's largest pharmaceutical companies — vaccines, oncology, and the drug pipeline behind them.

Coverage of Pfizer is rising : 4 signals on the latest tracked day, down 33% from its three-week baseline of 6, across 4 domains (unchanged from a week ago). That makes it the #335 most-covered of the 349 concerns we track.

If Pfizer matters to your work, coverage is climbing off its baseline — worth a closer-than-usual look this week.

What’s changed

6 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.

What the reporting says

Across 24 tracked stories from 15 outlets, reporting on Pfizer most often describes regulatory approvals (5), launches or releases (1), price levels (1).

It shows up alongside FDA (9), Bristol Myers Squibb (8), Merck (8).

Two steps out: AI (through FDA, 9 shared stories on the weaker link); Cder (through FDA, 9 shared stories on the weaker link); Clinical Trials (through FDA, 9 shared stories on the weaker link); Colorectal Cancer (through FDA, 9 shared stories on the weaker link).

Tracked since Jun 25, with coverage on 8 separate days — concentrated in Biotech Pharma and Preprint.

What the crowd is pricing

Coverage momentum and market odds are separate readings — one can move without the other. A price is what the crowd believes, shown as a signal, not a forecast of ours.
Ask the engine about Pfizer + Track Pfizer for a daily read
Counts computed from our committed signal record (Jul 15 – Aug 29, 10 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 29, 1:42 PM PT